WO2015052264A1 - Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators - Google Patents
Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators Download PDFInfo
- Publication number
- WO2015052264A1 WO2015052264A1 PCT/EP2014/071593 EP2014071593W WO2015052264A1 WO 2015052264 A1 WO2015052264 A1 WO 2015052264A1 EP 2014071593 W EP2014071593 W EP 2014071593W WO 2015052264 A1 WO2015052264 A1 WO 2015052264A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- haloalkyl
- halogen
- compound
- independently selected
- Prior art date
Links
- 0 CC(*)[C@@]1(*)N(*)C(*)(*)C1(*)* Chemical compound CC(*)[C@@]1(*)N(*)C(*)(*)C1(*)* 0.000 description 50
- GUVJJZHGUBAILY-UHFFFAOYSA-N NCc1ncnc(-c2cnc(C(F)(F)F)cc2)c1 Chemical compound NCc1ncnc(-c2cnc(C(F)(F)F)cc2)c1 GUVJJZHGUBAILY-UHFFFAOYSA-N 0.000 description 3
- RDRQUUWCJTYHCT-UHFFFAOYSA-N FC(C1CCNCC1)(F)F Chemical compound FC(C1CCNCC1)(F)F RDRQUUWCJTYHCT-UHFFFAOYSA-N 0.000 description 2
- MGBLEYLTQUIXOU-UHFFFAOYSA-N N#Cc1ncnc(-c(cc2)ccc2OC(F)(F)F)c1 Chemical compound N#Cc1ncnc(-c(cc2)ccc2OC(F)(F)F)c1 MGBLEYLTQUIXOU-UHFFFAOYSA-N 0.000 description 2
- JUDUWUJIMAUTLC-UHFFFAOYSA-N NCc1cc(-c(cc2)ccc2OC(F)(F)F)ncn1 Chemical compound NCc1cc(-c(cc2)ccc2OC(F)(F)F)ncn1 JUDUWUJIMAUTLC-UHFFFAOYSA-N 0.000 description 2
- LXTVWPLNTOGEDG-UHFFFAOYSA-N NCc1ncnc(C(CC2)=CCC2C(F)(F)F)c1 Chemical compound NCc1ncnc(C(CC2)=CCC2C(F)(F)F)c1 LXTVWPLNTOGEDG-UHFFFAOYSA-N 0.000 description 2
- LFLSATHZMYYIAQ-UHFFFAOYSA-N NS(c(cc1)ccc1F)(=O)=O Chemical compound NS(c(cc1)ccc1F)(=O)=O LFLSATHZMYYIAQ-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N O=C(c1c2cccc1)NC2=O Chemical compound O=C(c1c2cccc1)NC2=O XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- UEPMOPONXHPRPN-UHFFFAOYSA-N C=CCC(COC1)C1=O Chemical compound C=CCC(COC1)C1=O UEPMOPONXHPRPN-UHFFFAOYSA-N 0.000 description 1
- DVVPXYBQHQSSCX-RNFRBKRXSA-N C=CC[C@H](COC1)[C@@H]1O Chemical compound C=CC[C@H](COC1)[C@@H]1O DVVPXYBQHQSSCX-RNFRBKRXSA-N 0.000 description 1
- VBBYQJZOFNKNJQ-UHFFFAOYSA-N CC(C(F)(F)F)(NC)NC Chemical compound CC(C(F)(F)F)(NC)NC VBBYQJZOFNKNJQ-UHFFFAOYSA-N 0.000 description 1
- FOLBVHWIPIAXPV-UHFFFAOYSA-N CC(C)(C)OC(C(C(C)=O)C(C(CC1)(CC2)CCC12C(OC)=O)=O)=O Chemical compound CC(C)(C)OC(C(C(C)=O)C(C(CC1)(CC2)CCC12C(OC)=O)=O)=O FOLBVHWIPIAXPV-UHFFFAOYSA-N 0.000 description 1
- SWMKUFSZMQRGQD-BJQOMGFOSA-N CC(C)(C)OC(N(CC(C1)(C2)C1(F)F)[C@@H]2C(NCc1ncnc(-c2cnc(C(F)(F)F)cc2)c1)=O)=O Chemical compound CC(C)(C)OC(N(CC(C1)(C2)C1(F)F)[C@@H]2C(NCc1ncnc(-c2cnc(C(F)(F)F)cc2)c1)=O)=O SWMKUFSZMQRGQD-BJQOMGFOSA-N 0.000 description 1
- OXXSWURHJYLTIL-RGENBBCFSA-N CC(C)(C)OC(N(CC(C1)(C2)C1(F)F)[C@@H]2C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC(C1)(C2)C1(F)F)[C@@H]2C(O)=O)=O OXXSWURHJYLTIL-RGENBBCFSA-N 0.000 description 1
- VNGZTEPKSFGGHK-HOCLYGCPSA-N CC(C)(C)OC(N(CC[C@@H]1F)[C@@H]1C(NCc1c[n](-c2ccc(C(F)(F)F)nc2)nc1OC)=O)=O Chemical compound CC(C)(C)OC(N(CC[C@@H]1F)[C@@H]1C(NCc1c[n](-c2ccc(C(F)(F)F)nc2)nc1OC)=O)=O VNGZTEPKSFGGHK-HOCLYGCPSA-N 0.000 description 1
- HTSIWDMMDZPLLY-SJORKVTESA-N CC(C)(C)OC(N(CC[C@H]1O)[C@@H]1C(NCc(cc(cc1)-c2cnc(C(F)(F)F)nc2)c1C(N)=O)=O)=O Chemical compound CC(C)(C)OC(N(CC[C@H]1O)[C@@H]1C(NCc(cc(cc1)-c2cnc(C(F)(F)F)nc2)c1C(N)=O)=O)=O HTSIWDMMDZPLLY-SJORKVTESA-N 0.000 description 1
- FUYYCVFXMRPFOK-ZBFHGGJFSA-N CC(C)(C)OC(N(CC[C@H]1O)[C@@H]1C(NCc1c[n](-c2ccc(C(F)(F)F)nc2)nc1OC)=O)=O Chemical compound CC(C)(C)OC(N(CC[C@H]1O)[C@@H]1C(NCc1c[n](-c2ccc(C(F)(F)F)nc2)nc1OC)=O)=O FUYYCVFXMRPFOK-ZBFHGGJFSA-N 0.000 description 1
- JLDHXHPQMBNKMC-RQJHMYQMSA-N CC(C)(C)OC(N(CC[C@H]1O)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC[C@H]1O)[C@@H]1C(O)=O)=O JLDHXHPQMBNKMC-RQJHMYQMSA-N 0.000 description 1
- QLZICOBLKDRKCV-AEFFLSMTSA-N CC(C)(C)OC(N(C[C@@H](C1)F)[C@@H]1C(NCc1cc(-c2ccc(C(F)(F)F)nc2)ncc1C#N)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)F)[C@@H]1C(NCc1cc(-c2ccc(C(F)(F)F)nc2)ncc1C#N)=O)=O QLZICOBLKDRKCV-AEFFLSMTSA-N 0.000 description 1
- STTPYEPDSNXMKF-NHTMILBNSA-N CC(C)(C)OC(N(C[C@@H](C1)F)[C@@H]1C(OC[N](CCC1)([C@@H]1C(NCc1cc(F)nc(-c2cnc(C(F)(F)F)cc2)c1)=O)C(OC(C)(C)C)=O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)F)[C@@H]1C(OC[N](CCC1)([C@@H]1C(NCc1cc(F)nc(-c2cnc(C(F)(F)F)cc2)c1)=O)C(OC(C)(C)C)=O)=O)=O STTPYEPDSNXMKF-NHTMILBNSA-N 0.000 description 1
- BENKAPCDIOILGV-RQJHMYQMSA-N CC(C)(C)OC(N(C[C@@H](C1)O)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)O)[C@@H]1C(O)=O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
- MZMNEDXVUJLQAF-SFYZADRCSA-N CC(C)(C)OC(N(C[C@@H](C1)O)[C@@H]1C(OC)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)O)[C@@H]1C(OC)=O)=O MZMNEDXVUJLQAF-SFYZADRCSA-N 0.000 description 1
- GDWDGTXIKZKLHO-AOWBMEDYSA-N CC(C)(C)OC(N(C[C@H](C1)O)[C@@H]1C(OCCC([C@H](C[C@H]1C(O)=O)O)N1C(OC(C)(C)C)=O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@H](C1)O)[C@@H]1C(OCCC([C@H](C[C@H]1C(O)=O)O)N1C(OC(C)(C)C)=O)=O)=O GDWDGTXIKZKLHO-AOWBMEDYSA-N 0.000 description 1
- WUGLCWKZOQOAAC-UHFFFAOYSA-N CC(CC(C(CCC1)(CC2)CC1C2C(OC)=O)=O)=O Chemical compound CC(CC(C(CCC1)(CC2)CC1C2C(OC)=O)=O)=O WUGLCWKZOQOAAC-UHFFFAOYSA-N 0.000 description 1
- PHZAPBNEMKQWNC-PKEIRNPWSA-N CC(C[C@H](C1)F)(C(O)=O)N1S(c(cc1)ccc1F)(=O)=O Chemical compound CC(C[C@H](C1)F)(C(O)=O)N1S(c(cc1)ccc1F)(=O)=O PHZAPBNEMKQWNC-PKEIRNPWSA-N 0.000 description 1
- BHUUQNRYSHOCTI-UHFFFAOYSA-N CC(OCc1nc(C)cc(-c2cnc(C(F)(F)F)nc2)c1)=O Chemical compound CC(OCc1nc(C)cc(-c2cnc(C(F)(F)F)nc2)c1)=O BHUUQNRYSHOCTI-UHFFFAOYSA-N 0.000 description 1
- CZZAQYXERNCLCV-PLNGDYQASA-N CC/C=C(/C(F)(F)F)\N(C)N Chemical compound CC/C=C(/C(F)(F)F)\N(C)N CZZAQYXERNCLCV-PLNGDYQASA-N 0.000 description 1
- UZTVGKBRJLKFAN-XQRVVYSFSA-N CC/C=C(/CN)\NC Chemical compound CC/C=C(/CN)\NC UZTVGKBRJLKFAN-XQRVVYSFSA-N 0.000 description 1
- NVSVNULBXHQCMH-MGCACWEGSA-N CC/C=C\C(\C(F)(F)F)=N/NC([C@H]([C@H](C[C@@H]12)CC1F)N2S(c(cc1)ccc1F)(=O)=O)=O Chemical compound CC/C=C\C(\C(F)(F)F)=N/NC([C@H]([C@H](C[C@@H]12)CC1F)N2S(c(cc1)ccc1F)(=O)=O)=O NVSVNULBXHQCMH-MGCACWEGSA-N 0.000 description 1
- DAERXQFIFQCGNJ-VSVJJMHFSA-N CC/C=C\C(\C(F)(F)F)=N/NC([C@H]([C@H](C[C@H]1C2)C2F)N1S(c(cc1)ccc1F)(=O)=O)=O Chemical compound CC/C=C\C(\C(F)(F)F)=N/NC([C@H]([C@H](C[C@H]1C2)C2F)N1S(c(cc1)ccc1F)(=O)=O)=O DAERXQFIFQCGNJ-VSVJJMHFSA-N 0.000 description 1
- OAESOLHYCLAFCD-GHXNOFRVSA-N CC/N=C(/C(F)(F)F)\N(C)C(C)OC Chemical compound CC/N=C(/C(F)(F)F)\N(C)C(C)OC OAESOLHYCLAFCD-GHXNOFRVSA-N 0.000 description 1
- SARWEPUHGNIVNJ-UHFFFAOYSA-N CC1(C)OB(c2ccnc(C#N)c2)OC1(C)C Chemical compound CC1(C)OB(c2ccnc(C#N)c2)OC1(C)C SARWEPUHGNIVNJ-UHFFFAOYSA-N 0.000 description 1
- XJHHJKRQUDXIKL-UHFFFAOYSA-N CC1(C)OB(c2cnc(C3CC3)cc2)OC1(C)C Chemical compound CC1(C)OB(c2cnc(C3CC3)cc2)OC1(C)C XJHHJKRQUDXIKL-UHFFFAOYSA-N 0.000 description 1
- OCAPJQXHZBPKSL-UHFFFAOYSA-N CC1N=C(C(F)(F)F)C=CC1 Chemical compound CC1N=C(C(F)(F)F)C=CC1 OCAPJQXHZBPKSL-UHFFFAOYSA-N 0.000 description 1
- LUNRMQNMMDICRB-YPVSKDHRSA-N CCC1N(C)[C@H](C2)[C@H]2C1 Chemical compound CCC1N(C)[C@H](C2)[C@H]2C1 LUNRMQNMMDICRB-YPVSKDHRSA-N 0.000 description 1
- PCRRGFYLBPYTGG-UHFFFAOYSA-N CCOC(C(C1C=CC2C1)N2OC(c1ccccc1)=O)=O Chemical compound CCOC(C(C1C=CC2C1)N2OC(c1ccccc1)=O)=O PCRRGFYLBPYTGG-UHFFFAOYSA-N 0.000 description 1
- UOQONHIIAWFMBH-FGFFJQAFSA-N CCOC(C1N[C@]2(CC(C)OC(C=O)=O)C=CC1C2)=O Chemical compound CCOC(C1N[C@]2(CC(C)OC(C=O)=O)C=CC1C2)=O UOQONHIIAWFMBH-FGFFJQAFSA-N 0.000 description 1
- JMHQESARJMGVCZ-RITPCOANSA-N CCOC([C@H](C1)NC[C@@H]1O)=O Chemical compound CCOC([C@H](C1)NC[C@@H]1O)=O JMHQESARJMGVCZ-RITPCOANSA-N 0.000 description 1
- VXHCBKUFAXDEDI-UHFFFAOYSA-N CCOC(c1c[nH]nc1OC)=O Chemical compound CCOC(c1c[nH]nc1OC)=O VXHCBKUFAXDEDI-UHFFFAOYSA-N 0.000 description 1
- IAMFKOXNUKLMAT-UHFFFAOYSA-N CCOC(c1c[n](-c2cnc(C(F)(F)F)cc2)nc1OC)=O Chemical compound CCOC(c1c[n](-c2cnc(C(F)(F)F)cc2)nc1OC)=O IAMFKOXNUKLMAT-UHFFFAOYSA-N 0.000 description 1
- HITQRFIKKVWKTJ-UHFFFAOYSA-N CCOC(c1cc(F)cc(-c2cnc(C(F)(F)F)cn2)c1)=O Chemical compound CCOC(c1cc(F)cc(-c2cnc(C(F)(F)F)cn2)c1)=O HITQRFIKKVWKTJ-UHFFFAOYSA-N 0.000 description 1
- MYCQIONEIWJTMP-UHFFFAOYSA-N CCOC(c1ncnc(C(CC2)=CCC2C(F)(F)F)c1)=O Chemical compound CCOC(c1ncnc(C(CC2)=CCC2C(F)(F)F)c1)=O MYCQIONEIWJTMP-UHFFFAOYSA-N 0.000 description 1
- OMDRIESTFYXUCI-UHFFFAOYSA-N CCc(cc(cc1)-c2cnc(C(F)(F)F)nc2)c1C(N)=O Chemical compound CCc(cc(cc1)-c2cnc(C(F)(F)F)nc2)c1C(N)=O OMDRIESTFYXUCI-UHFFFAOYSA-N 0.000 description 1
- LQVIEHMXGCSDLJ-UHFFFAOYSA-N CCc1nc(C(F)(F)F)c[s]1 Chemical compound CCc1nc(C(F)(F)F)c[s]1 LQVIEHMXGCSDLJ-UHFFFAOYSA-N 0.000 description 1
- GENRMUUSRZVCQV-UHFFFAOYSA-N CN(CC1)CCC1C(F)(F)F Chemical compound CN(CC1)CCC1C(F)(F)F GENRMUUSRZVCQV-UHFFFAOYSA-N 0.000 description 1
- QDULOCGCFXNHMW-SFYZADRCSA-N CN1C2(CC2)C[C@H]2[C@@H]1COC2 Chemical compound CN1C2(CC2)C[C@H]2[C@@H]1COC2 QDULOCGCFXNHMW-SFYZADRCSA-N 0.000 description 1
- WMQGNSKTQDGSOF-OQFOIZHKSA-N CO/N=C(/C(F)(F)F)\N=C Chemical compound CO/N=C(/C(F)(F)F)\N=C WMQGNSKTQDGSOF-OQFOIZHKSA-N 0.000 description 1
- ONEQKBWHWADWGQ-UHFFFAOYSA-N COC(c1cc(-c2cnc(C(F)(F)F)nc2)ncc1Cl)=O Chemical compound COC(c1cc(-c2cnc(C(F)(F)F)nc2)ncc1Cl)=O ONEQKBWHWADWGQ-UHFFFAOYSA-N 0.000 description 1
- IAEUEOUJKNGPMO-UHFFFAOYSA-N COC(c1ncnc(Cl)c1)=O Chemical compound COC(c1ncnc(Cl)c1)=O IAEUEOUJKNGPMO-UHFFFAOYSA-N 0.000 description 1
- XHKGHNXYECYEEH-UHFFFAOYSA-N COCCOc(nc(C(F)(F)F)cc1)c1-c1cc(CN(C(c2ccccc22)=O)C2=O)cc(F)c1 Chemical compound COCCOc(nc(C(F)(F)F)cc1)c1-c1cc(CN(C(c2ccccc22)=O)C2=O)cc(F)c1 XHKGHNXYECYEEH-UHFFFAOYSA-N 0.000 description 1
- SVQSOUPVLJBJMZ-UHFFFAOYSA-N COCCOc1nc(C(F)(F)F)ccc1-c1cc(C(OC)=O)cc(F)c1 Chemical compound COCCOc1nc(C(F)(F)F)ccc1-c1cc(C(OC)=O)cc(F)c1 SVQSOUPVLJBJMZ-UHFFFAOYSA-N 0.000 description 1
- QNLQGGQQZWVKLU-UHFFFAOYSA-N COCCOc1nc(C(F)(F)F)ccc1-c1cc(COC)cc(F)c1 Chemical compound COCCOc1nc(C(F)(F)F)ccc1-c1cc(COC)cc(F)c1 QNLQGGQQZWVKLU-UHFFFAOYSA-N 0.000 description 1
- MUFOAUHUUCBBCG-OMCISZLKSA-N COc(c(/C=N/O)c1)n[n]1-c1ccc(C(F)(F)F)cc1 Chemical compound COc(c(/C=N/O)c1)n[n]1-c1ccc(C(F)(F)F)cc1 MUFOAUHUUCBBCG-OMCISZLKSA-N 0.000 description 1
- STXTWXWQOLFGDY-UHFFFAOYSA-N COc(c(C=O)c1)n[n]1-c1ccc(C(F)(F)F)cc1 Chemical compound COc(c(C=O)c1)n[n]1-c1ccc(C(F)(F)F)cc1 STXTWXWQOLFGDY-UHFFFAOYSA-N 0.000 description 1
- SPZXKDQRCXFRIK-MBWSXKIYSA-N COc1cnc(CNC([C@H](C[C@H](C2)F)N2S([C@@H](CC2)C2F)(=O)=O)=O)cc1-c1cnc(C(F)(F)F)cc1 Chemical compound COc1cnc(CNC([C@H](C[C@H](C2)F)N2S([C@@H](CC2)C2F)(=O)=O)=O)cc1-c1cnc(C(F)(F)F)cc1 SPZXKDQRCXFRIK-MBWSXKIYSA-N 0.000 description 1
- XBHAAZVJGKNKDH-IBGZPJMESA-N COc1nc(CNC([C@H](CCC2)N2S(c(cc2)ccc2F)(=O)=O)=O)cc(-c2ccc(C(F)(F)F)nc2)n1 Chemical compound COc1nc(CNC([C@H](CCC2)N2S(c(cc2)ccc2F)(=O)=O)=O)cc(-c2ccc(C(F)(F)F)nc2)n1 XBHAAZVJGKNKDH-IBGZPJMESA-N 0.000 description 1
- DPJHZJGAGIWXTD-UHFFFAOYSA-N CS(c(cc1)ccc1F)(=O)=O Chemical compound CS(c(cc1)ccc1F)(=O)=O DPJHZJGAGIWXTD-UHFFFAOYSA-N 0.000 description 1
- BBCFRTHODCIVDP-XOBRGWDASA-N C[C@@H](CC[C@H]1C(NCc2cc(-c3ccc(C(F)(F)F)nc3)ncn2)=O)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@@H](CC[C@H]1C(NCc2cc(-c3ccc(C(F)(F)F)nc3)ncn2)=O)N1S(c(cc1)ccc1F)(=O)=O BBCFRTHODCIVDP-XOBRGWDASA-N 0.000 description 1
- WYXGQTJNYMMMLO-ORAYPTAESA-N C[C@@H](C[C@@H]1C(NCc2ncnc(-c3cnc(C(F)(F)F)cc3)c2)=O)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@@H](C[C@@H]1C(NCc2ncnc(-c3cnc(C(F)(F)F)cc3)c2)=O)N1S(c(cc1)ccc1F)(=O)=O WYXGQTJNYMMMLO-ORAYPTAESA-N 0.000 description 1
- HFJZCGUXBLVWRY-QFIPXVFZSA-N C[C@](CCC1)(C(NCc2cc(-c3ncc(C(F)(F)F)cc3)ncn2)=O)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@](CCC1)(C(NCc2cc(-c3ncc(C(F)(F)F)cc3)ncn2)=O)N1S(c(cc1)ccc1F)(=O)=O HFJZCGUXBLVWRY-QFIPXVFZSA-N 0.000 description 1
- NLQHZPSBTDCROM-LBPRGKRZSA-N C[C@](CCC1)(C(O)=O)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@](CCC1)(C(O)=O)N1S(c(cc1)ccc1F)(=O)=O NLQHZPSBTDCROM-LBPRGKRZSA-N 0.000 description 1
- NWSIRYGEZSHVOK-JPYJTQIMSA-N C[C@](C[C@H](C1)F)(C(NCc2cc(-c3ccc(C(F)(F)F)cc3)ncn2)=O)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@](C[C@H](C1)F)(C(NCc2cc(-c3ccc(C(F)(F)F)cc3)ncn2)=O)N1S(c(cc1)ccc1F)(=O)=O NWSIRYGEZSHVOK-JPYJTQIMSA-N 0.000 description 1
- OQZWREUZQUVLKY-UHFFFAOYSA-N Cc(c(C(OC)=O)c1)cnc1-c1cnc(C(F)(F)F)nc1 Chemical compound Cc(c(C(OC)=O)c1)cnc1-c1cnc(C(F)(F)F)nc1 OQZWREUZQUVLKY-UHFFFAOYSA-N 0.000 description 1
- GPGIVEOCMLWIRK-UHFFFAOYSA-N Cc(c(CN(C(c1c2cccc1)=O)C2=O)c1)cnc1-c1cnc(C(F)(F)F)nc1 Chemical compound Cc(c(CN(C(c1c2cccc1)=O)C2=O)c1)cnc1-c1cnc(C(F)(F)F)nc1 GPGIVEOCMLWIRK-UHFFFAOYSA-N 0.000 description 1
- QKUGHPJQPSRQRF-UHFFFAOYSA-N Cc(c(CO)c1)cnc1-c1cnc(C(F)(F)F)nc1 Chemical compound Cc(c(CO)c1)cnc1-c1cnc(C(F)(F)F)nc1 QKUGHPJQPSRQRF-UHFFFAOYSA-N 0.000 description 1
- JUXFXYQUXNXVAA-UHFFFAOYSA-N Cc(cc1)ccc1OC(F)(F)F Chemical compound Cc(cc1)ccc1OC(F)(F)F JUXFXYQUXNXVAA-UHFFFAOYSA-N 0.000 description 1
- BYVBIFQYLVHGER-UHFFFAOYSA-N Cc1cc(OC)c(C[BrH]Cc2cc(OC)cc(Br)c2)c(Br)c1 Chemical compound Cc1cc(OC)c(C[BrH]Cc2cc(OC)cc(Br)c2)c(Br)c1 BYVBIFQYLVHGER-UHFFFAOYSA-N 0.000 description 1
- LRLRAYMYEXQKID-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)cc1 Chemical compound Cc1ccc(C(F)(F)F)cc1 LRLRAYMYEXQKID-UHFFFAOYSA-N 0.000 description 1
- HALCBPJUGWBVBU-UHFFFAOYSA-N Cc1cnc(C(F)(F)F)cc1 Chemical compound Cc1cnc(C(F)(F)F)cc1 HALCBPJUGWBVBU-UHFFFAOYSA-N 0.000 description 1
- ZBCOTWQYKCHKQK-UHFFFAOYSA-N Cc1ncc(C(F)(F)F)cc1 Chemical compound Cc1ncc(C(F)(F)F)cc1 ZBCOTWQYKCHKQK-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N Clc1cc(Cl)ncn1 Chemical compound Clc1cc(Cl)ncn1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- NGSKFMPSBUAUNE-UHFFFAOYSA-N Clc1nc(Cl)cc(I)c1 Chemical compound Clc1nc(Cl)cc(I)c1 NGSKFMPSBUAUNE-UHFFFAOYSA-N 0.000 description 1
- QREFFYXXKYXRDA-UHFFFAOYSA-N FC(C(CC1)CCN1c1cc(Cl)ncc1F)(F)F Chemical compound FC(C(CC1)CCN1c1cc(Cl)ncc1F)(F)F QREFFYXXKYXRDA-UHFFFAOYSA-N 0.000 description 1
- RJUJXISXQHJQHE-UHFFFAOYSA-N FC(C(CC1)CCN1c1cc(Cl)ncn1)(F)F Chemical compound FC(C(CC1)CCN1c1cc(Cl)ncn1)(F)F RJUJXISXQHJQHE-UHFFFAOYSA-N 0.000 description 1
- VWYXYPHLXKGBSE-UHFFFAOYSA-N FC(C(CC1CC2)CC2N1c(cc(nc1)Cl)c1F)(F)F Chemical compound FC(C(CC1CC2)CC2N1c(cc(nc1)Cl)c1F)(F)F VWYXYPHLXKGBSE-UHFFFAOYSA-N 0.000 description 1
- ADSOSOUJVRZMFX-UHFFFAOYSA-N FC(C1CC(CC2)NC2C1)(F)F Chemical compound FC(C1CC(CC2)NC2C1)(F)F ADSOSOUJVRZMFX-UHFFFAOYSA-N 0.000 description 1
- MCHUERUQEQRXLD-UHFFFAOYSA-N FC(Oc(cc1)ccc1-c1cc(Cl)ncn1)(F)F Chemical compound FC(Oc(cc1)ccc1-c1cc(Cl)ncn1)(F)F MCHUERUQEQRXLD-UHFFFAOYSA-N 0.000 description 1
- QLBZTXKTAXTMCF-UHFFFAOYSA-N FC(c(cc1)cnc1-c1cc(Cl)nc(Cl)c1)(F)F Chemical compound FC(c(cc1)cnc1-c1cc(Cl)nc(Cl)c1)(F)F QLBZTXKTAXTMCF-UHFFFAOYSA-N 0.000 description 1
- ZINKGLDVGWXXQS-UHFFFAOYSA-N FC(c(cc1)cnc1-c1cc(Cl)nc(F)c1)(F)F Chemical compound FC(c(cc1)cnc1-c1cc(Cl)nc(F)c1)(F)F ZINKGLDVGWXXQS-UHFFFAOYSA-N 0.000 description 1
- GSKMWMFOQQBVMI-UHFFFAOYSA-N FC(c(cc1)cnc1Br)(F)F Chemical compound FC(c(cc1)cnc1Br)(F)F GSKMWMFOQQBVMI-UHFFFAOYSA-N 0.000 description 1
- SJZVYMAEMMJYMI-UHFFFAOYSA-N FC(c(cc1)ncc1-c1cc(Cl)ncc1F)(F)F Chemical compound FC(c(cc1)ncc1-c1cc(Cl)ncc1F)(F)F SJZVYMAEMMJYMI-UHFFFAOYSA-N 0.000 description 1
- RPFAUCIXZGMCFN-UHFFFAOYSA-N FC(c(cc1)ncc1Br)(F)F Chemical compound FC(c(cc1)ncc1Br)(F)F RPFAUCIXZGMCFN-UHFFFAOYSA-N 0.000 description 1
- QEJBDKUYODYHBX-UHFFFAOYSA-N FC(c(nc1)ncc1-c1cc(Cl)nc(Cl)c1)(F)F Chemical compound FC(c(nc1)ncc1-c1cc(Cl)nc(Cl)c1)(F)F QEJBDKUYODYHBX-UHFFFAOYSA-N 0.000 description 1
- CRLPRXQOSARJCF-UHFFFAOYSA-N Fc(c(I)c1)cnc1Cl Chemical compound Fc(c(I)c1)cnc1Cl CRLPRXQOSARJCF-UHFFFAOYSA-N 0.000 description 1
- RAFNXCFHDBOGRJ-UHFFFAOYSA-N N#Cc(cc1-c2cnc(C(F)(F)F)cc2)ncc1F Chemical compound N#Cc(cc1-c2cnc(C(F)(F)F)cc2)ncc1F RAFNXCFHDBOGRJ-UHFFFAOYSA-N 0.000 description 1
- ULPYOGCEDACOBS-XXBNENTESA-N N#Cc(cnc(CNC([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)=O)c1)c1-c1ccc(C(F)(F)F)cc1 Chemical compound N#Cc(cnc(CNC([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)=O)c1)c1-c1ccc(C(F)(F)F)cc1 ULPYOGCEDACOBS-XXBNENTESA-N 0.000 description 1
- QCPBLUBTTYBKFC-UTKZUKDTSA-N N#Cc(cnc(CNC([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)=O)c1)c1-c1ccc(C(F)(F)F)nc1 Chemical compound N#Cc(cnc(CNC([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)=O)c1)c1-c1ccc(C(F)(F)F)nc1 QCPBLUBTTYBKFC-UTKZUKDTSA-N 0.000 description 1
- HOMIRMKHEGRRRG-HIFRSBDPSA-N N#Cc1c(CNC([C@H](C2)NC[C@@H]2F)=O)cc(-c2cnc(C(F)(F)F)cc2)nc1 Chemical compound N#Cc1c(CNC([C@H](C2)NC[C@@H]2F)=O)cc(-c2cnc(C(F)(F)F)cc2)nc1 HOMIRMKHEGRRRG-HIFRSBDPSA-N 0.000 description 1
- CSJFBICLRDOKPW-VKJRYQNVSA-N N#Cc1cc(CNC([C@H](C[C@H](C2)F)N2S(c(c(Cc2cc(-c3cc(Br)cc(CNC([C@H](C[C@H](C4)F)N4S(c(cc4)ccc4F)(=O)=O)=O)c3)cnc2C(F)(F)F)c2)ccc2F)(=O)=O)=O)cc(-c2cnc(C(F)(F)F)cc2)c1 Chemical compound N#Cc1cc(CNC([C@H](C[C@H](C2)F)N2S(c(c(Cc2cc(-c3cc(Br)cc(CNC([C@H](C[C@H](C4)F)N4S(c(cc4)ccc4F)(=O)=O)=O)c3)cnc2C(F)(F)F)c2)ccc2F)(=O)=O)=O)cc(-c2cnc(C(F)(F)F)cc2)c1 CSJFBICLRDOKPW-VKJRYQNVSA-N 0.000 description 1
- AXQJVQXCBOVMTN-UHFFFAOYSA-N N#Cc1nc(F)cc(-c2ncc(C(F)(F)F)cc2)c1 Chemical compound N#Cc1nc(F)cc(-c2ncc(C(F)(F)F)cc2)c1 AXQJVQXCBOVMTN-UHFFFAOYSA-N 0.000 description 1
- YBIBMHRDDYADSJ-UHFFFAOYSA-N NC1(N)Oc2cc(I)ccc2O1 Chemical compound NC1(N)Oc2cc(I)ccc2O1 YBIBMHRDDYADSJ-UHFFFAOYSA-N 0.000 description 1
- FDTOWLADUQURPB-UHFFFAOYSA-N NCc1cc(F)nc(-c2cnc(C(F)(F)F)cc2)c1 Chemical compound NCc1cc(F)nc(-c2cnc(C(F)(F)F)cc2)c1 FDTOWLADUQURPB-UHFFFAOYSA-N 0.000 description 1
- BQPUKVMIUMZBOY-UHFFFAOYSA-N NCc1ncnc(-c2ccc(C(F)(F)F)cc2)c1 Chemical compound NCc1ncnc(-c2ccc(C(F)(F)F)cc2)c1 BQPUKVMIUMZBOY-UHFFFAOYSA-N 0.000 description 1
- RWNIFJVAJMHETA-UHFFFAOYSA-N NCc1ncnc(-c2ccc(C(F)(F)F)cn2)c1 Chemical compound NCc1ncnc(-c2ccc(C(F)(F)F)cn2)c1 RWNIFJVAJMHETA-UHFFFAOYSA-N 0.000 description 1
- FKUAPUZEIDRVKZ-UHFFFAOYSA-N NCc1ncnc(-c2cnc(C(F)(F)F)nc2)c1 Chemical compound NCc1ncnc(-c2cnc(C(F)(F)F)nc2)c1 FKUAPUZEIDRVKZ-UHFFFAOYSA-N 0.000 description 1
- KSILMCDYDAKOJD-UHFFFAOYSA-N NN(C(c1ccccc11)=O)C1=O Chemical compound NN(C(c1ccccc11)=O)C1=O KSILMCDYDAKOJD-UHFFFAOYSA-N 0.000 description 1
- CKMKBOOHEVCTNT-YPMHNXCESA-N O=C([C@H](C1)NC[C@@H]1F)NCc1cc(Cl)nc(-c2ccc(C(F)(F)F)nc2)c1 Chemical compound O=C([C@H](C1)NC[C@@H]1F)NCc1cc(Cl)nc(-c2ccc(C(F)(F)F)nc2)c1 CKMKBOOHEVCTNT-YPMHNXCESA-N 0.000 description 1
- YMYZWQQLVKZYPS-MNOVXSKESA-N O=C([C@H](C1)NC[C@@H]1F)NCc1cc(F)cc(Br)c1 Chemical compound O=C([C@H](C1)NC[C@@H]1F)NCc1cc(F)cc(Br)c1 YMYZWQQLVKZYPS-MNOVXSKESA-N 0.000 description 1
- RAXIGXRQEZFHGM-NRFANRHFSA-N O=C([C@H](CCC1)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(-c(cc2)ccc2OC(F)(F)F)ncn1 Chemical compound O=C([C@H](CCC1)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(-c(cc2)ccc2OC(F)(F)F)ncn1 RAXIGXRQEZFHGM-NRFANRHFSA-N 0.000 description 1
- FVEVYUOVLKEWMT-YJYMSZOUSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)cc(F)c1F)(=O)=O)NCc1cc(-c2ccc(C(F)(F)F)nc2)ncn1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)cc(F)c1F)(=O)=O)NCc1cc(-c2ccc(C(F)(F)F)nc2)ncn1 FVEVYUOVLKEWMT-YJYMSZOUSA-N 0.000 description 1
- DMLDAUYAJBPNMF-VLIAUNLRSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc(nc1)cc(-c2cnc(C(F)(F)F)c(F)c2)c1F Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc(nc1)cc(-c2cnc(C(F)(F)F)c(F)c2)c1F DMLDAUYAJBPNMF-VLIAUNLRSA-N 0.000 description 1
- MOCHTZHSWMIZAF-UZLBHIALSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(-c2ccc(C(F)F)nc2)nc(Cl)c1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(-c2ccc(C(F)F)nc2)nc(Cl)c1 MOCHTZHSWMIZAF-UZLBHIALSA-N 0.000 description 1
- ZKMARFBVNODTEA-MULNXWOJSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(C(CC2)(CC3)CCC23C(F)F)ncn1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(C(CC2)(CC3)CCC23C(F)F)ncn1 ZKMARFBVNODTEA-MULNXWOJSA-N 0.000 description 1
- JHXOWAOGHMUCFO-IDLMPWNNSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(C(CC2)=CCC2C(F)(F)F)ncn1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(C(CC2)=CCC2C(F)(F)F)ncn1 JHXOWAOGHMUCFO-IDLMPWNNSA-N 0.000 description 1
- TVVQCFOIOIBUOF-UTKZUKDTSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(F)cc(-c2ncc(C(F)F)nc2)c1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(F)cc(-c2ncc(C(F)F)nc2)c1 TVVQCFOIOIBUOF-UTKZUKDTSA-N 0.000 description 1
- BAWHCCGAFJHJOB-HIFRSBDPSA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1ccnc(Br)c1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1ccnc(Br)c1 BAWHCCGAFJHJOB-HIFRSBDPSA-N 0.000 description 1
- PUOGINDCHOJOMG-APWZRJJASA-N O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1ncnc(N(CC2)CCC2C(F)(F)F)c1 Chemical compound O=C([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)NCc1ncnc(N(CC2)CCC2C(F)(F)F)c1 PUOGINDCHOJOMG-APWZRJJASA-N 0.000 description 1
- PRCKQIDYJROCLA-HXOBKFHXSA-N O=C([C@](C1)([C@@H]1CC1)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(F)cc(-c2cnc(C(F)(F)F)nc2)c1 Chemical compound O=C([C@](C1)([C@@H]1CC1)N1S(c(cc1)ccc1F)(=O)=O)NCc1cc(F)cc(-c2cnc(C(F)(F)F)nc2)c1 PRCKQIDYJROCLA-HXOBKFHXSA-N 0.000 description 1
- OKKYHLPSUZAUEX-UHFFFAOYSA-N O=C(c1c2cccc1)N(Cc(cc1-c3cnc(C(F)(F)F)cc3)ncc1Cl)C2=O Chemical compound O=C(c1c2cccc1)N(Cc(cc1-c3cnc(C(F)(F)F)cc3)ncc1Cl)C2=O OKKYHLPSUZAUEX-UHFFFAOYSA-N 0.000 description 1
- KBERDYKNXNNCNQ-UHFFFAOYSA-N O=C(c1c2cccc1)N(Cc1ncnc(C(CC3)=CCC3C(F)(F)F)c1)C2=O Chemical compound O=C(c1c2cccc1)N(Cc1ncnc(C(CC3)=CCC3C(F)(F)F)c1)C2=O KBERDYKNXNNCNQ-UHFFFAOYSA-N 0.000 description 1
- KMBLGOMYUYJQKX-UHFFFAOYSA-N O=C(c1ccccc11)N(Cc2cc(Br)ncc2F)C1=O Chemical compound O=C(c1ccccc11)N(Cc2cc(Br)ncc2F)C1=O KMBLGOMYUYJQKX-UHFFFAOYSA-N 0.000 description 1
- JFUQZFQJFYZZGY-UHFFFAOYSA-N OB(c1cc(Cl)nc(Cl)c1)O Chemical compound OB(c1cc(Cl)nc(Cl)c1)O JFUQZFQJFYZZGY-UHFFFAOYSA-N 0.000 description 1
- OEZMIKKBMMAABO-UHFFFAOYSA-N OB(c1cnc(C(F)(F)F)nc1)O Chemical compound OB(c1cnc(C(F)(F)F)nc1)O OEZMIKKBMMAABO-UHFFFAOYSA-N 0.000 description 1
- ZQCPVISGDBHSPJ-UHFFFAOYSA-N OC(C(C(CC1C2)C2F)N1S(c(cc1)ccc1F)(=O)=O)=O Chemical compound OC(C(C(CC1C2)C2F)N1S(c(cc1)ccc1F)(=O)=O)=O ZQCPVISGDBHSPJ-UHFFFAOYSA-N 0.000 description 1
- ISYUAFVYETYRPO-JTQLQIEISA-N OC([C@H](CCC1)N1S(c(cc1)ccc1F)(=O)=O)=O Chemical compound OC([C@H](CCC1)N1S(c(cc1)ccc1F)(=O)=O)=O ISYUAFVYETYRPO-JTQLQIEISA-N 0.000 description 1
- YGWDWTKEODYXGV-SCZZXKLOSA-N OC([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)=O Chemical compound OC([C@H](C[C@H](C1)F)N1S(c(cc1)ccc1F)(=O)=O)=O YGWDWTKEODYXGV-SCZZXKLOSA-N 0.000 description 1
- QFFFXLLUGUHIHH-UHFFFAOYSA-N OC(c(c(I)c1)cnc1Cl)=O Chemical compound OC(c(c(I)c1)cnc1Cl)=O QFFFXLLUGUHIHH-UHFFFAOYSA-N 0.000 description 1
- UAWMVMPAYRWUFX-UHFFFAOYSA-N OC(c(cc1)cnc1Cl)=O Chemical compound OC(c(cc1)cnc1Cl)=O UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 1
- HNNGILPJISZBHG-UHFFFAOYSA-N OC(c1ncnc(-c2cnc(C3CC3)cc2)c1)=O Chemical compound OC(c1ncnc(-c2cnc(C3CC3)cc2)c1)=O HNNGILPJISZBHG-UHFFFAOYSA-N 0.000 description 1
- KQMVUTPTMBNBQL-UHFFFAOYSA-N OCc(cc(nc1)Br)c1F Chemical compound OCc(cc(nc1)Br)c1F KQMVUTPTMBNBQL-UHFFFAOYSA-N 0.000 description 1
- OHOPIXITOQXFTK-UHFFFAOYSA-N OCc(cc1-c2cnc(C(F)(F)F)cc2)ncc1Cl Chemical compound OCc(cc1-c2cnc(C(F)(F)F)cc2)ncc1Cl OHOPIXITOQXFTK-UHFFFAOYSA-N 0.000 description 1
- PQGUOWFAAGAXPD-UHFFFAOYSA-N OCc1cc(F)cc(-c2cnc(C(F)(F)F)cn2)c1 Chemical compound OCc1cc(F)cc(-c2cnc(C(F)(F)F)cn2)c1 PQGUOWFAAGAXPD-UHFFFAOYSA-N 0.000 description 1
- ZSBITZXZYYOIFX-UHFFFAOYSA-N OCc1ncnc(-c2cnc(C3CC3)cc2)c1 Chemical compound OCc1ncnc(-c2cnc(C3CC3)cc2)c1 ZSBITZXZYYOIFX-UHFFFAOYSA-N 0.000 description 1
- ROSXQHIIYDYVGK-UHFFFAOYSA-N OCc1ncnc(C(CC2)=CCC2C(F)(F)F)c1 Chemical compound OCc1ncnc(C(CC2)=CCC2C(F)(F)F)c1 ROSXQHIIYDYVGK-UHFFFAOYSA-N 0.000 description 1
- WXKJELJVZPLAGL-ZJUUUORDSA-N O[C@H](C[C@H]1C(O)=O)CN1OC(c1ccccc1)=O Chemical compound O[C@H](C[C@H]1C(O)=O)CN1OC(c1ccccc1)=O WXKJELJVZPLAGL-ZJUUUORDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES14789194T ES2713323T3 (es) | 2013-10-11 | 2014-10-09 | Compuestos de sulfonamida heterocíclicos sustituidos útiles como moduladores de trpa1 |
DK14789194.9T DK3055302T3 (en) | 2013-10-11 | 2014-10-09 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators |
LTEP14789194.9T LT3055302T (lt) | 2013-10-11 | 2014-10-09 | Pakeistieji heterocikliniai sulfonamidiniai junginiai, tinkami naudoti kaip trpa1 moduliatoriai |
PL14789194T PL3055302T3 (pl) | 2013-10-11 | 2014-10-09 | Podstawione związki heterocykliczne sulfonamidowe użyteczne jako modulatory TRPA1 |
EP14789194.9A EP3055302B1 (en) | 2013-10-11 | 2014-10-09 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
RU2016115868A RU2675792C2 (ru) | 2013-10-11 | 2014-10-09 | Замещенные гетероциклические сульфонамидные соединения, полезные в качестве модуляторов trpa 1 |
JP2016522013A JP2016532673A (ja) | 2013-10-11 | 2014-10-09 | Trpa1調節因子として有用な置換複素環式スルホンアミド化合物 |
RS20190254A RS58376B1 (sr) | 2013-10-11 | 2014-10-09 | Supstituisana heterociklična sulfonamidna jedinjenja korisna kao modulatori trpa1 |
MX2016002368A MX363457B (es) | 2013-10-11 | 2014-10-09 | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). |
SI201431098T SI3055302T1 (sl) | 2013-10-11 | 2014-10-09 | Substituirane heterociklične sulfonamidne spojine, uporabne kot modulatorji beljakovine TRPA1 |
KR1020167012211A KR20160064230A (ko) | 2013-10-11 | 2014-10-09 | Trpa1 조절제로서 유용한 치환된 헤테로환형 설폰아마이드 화합물 |
CR20170140A CR20170140A (es) | 2014-09-12 | 2014-10-09 | Compuestos de sulfonamida heterocíclica sustituída útiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1) |
BR112016002012A BR112016002012A2 (pt) | 2013-10-11 | 2014-10-09 | compostos de sulfonamida heterocíclica substituída úteis como moduladores de trpa1 |
SG11201609411SA SG11201609411SA (en) | 2013-10-11 | 2014-10-09 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
CA2917193A CA2917193A1 (en) | 2013-10-11 | 2014-10-09 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
CN201480053713.2A CN105612153B (zh) | 2013-10-11 | 2014-10-09 | 用作trpa1调节剂的取代的杂环磺酰胺化合物 |
US15/095,467 US20160221945A1 (en) | 2013-10-11 | 2016-04-11 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
HK16107470.6A HK1219478A1 (zh) | 2013-10-11 | 2016-06-27 | 用作 調節劑的取代的雜環磺酰胺化合物 |
US15/851,322 US20180118680A1 (en) | 2013-10-11 | 2017-12-21 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
US16/001,770 US20180282272A1 (en) | 2013-10-11 | 2018-06-06 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
HRP20190329TT HRP20190329T1 (hr) | 2013-10-11 | 2019-02-19 | Supstituirani heterociklički spojevi sulfonamida korisni za primjenu kao modulatori proteina trpa1 |
US16/657,102 US11236046B2 (en) | 2013-10-11 | 2019-10-18 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890127P | 2013-10-11 | 2013-10-11 | |
US61/890,127 | 2013-10-11 | ||
CN2014086380 | 2014-09-12 | ||
CNPCT/CN2014/086380 | 2014-09-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/095,467 Continuation US20160221945A1 (en) | 2013-10-11 | 2016-04-11 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
US15/851,322 Continuation US20180118680A1 (en) | 2013-10-11 | 2017-12-21 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015052264A1 true WO2015052264A1 (en) | 2015-04-16 |
Family
ID=51794850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/071593 WO2015052264A1 (en) | 2013-10-11 | 2014-10-09 | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
Country Status (23)
Country | Link |
---|---|
US (4) | US20160221945A1 (ja) |
EP (1) | EP3055302B1 (ja) |
JP (2) | JP2016532673A (ja) |
KR (1) | KR20160064230A (ja) |
CN (1) | CN105612153B (ja) |
BR (1) | BR112016002012A2 (ja) |
CA (1) | CA2917193A1 (ja) |
DK (1) | DK3055302T3 (ja) |
ES (1) | ES2713323T3 (ja) |
HK (1) | HK1219478A1 (ja) |
HR (1) | HRP20190329T1 (ja) |
HU (1) | HUE041652T2 (ja) |
LT (1) | LT3055302T (ja) |
MX (1) | MX363457B (ja) |
PL (1) | PL3055302T3 (ja) |
PT (1) | PT3055302T (ja) |
RS (1) | RS58376B1 (ja) |
RU (1) | RU2675792C2 (ja) |
SG (1) | SG11201609411SA (ja) |
SI (1) | SI3055302T1 (ja) |
TR (1) | TR201902249T4 (ja) |
TW (1) | TWI657076B (ja) |
WO (1) | WO2015052264A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016128529A1 (en) * | 2015-02-15 | 2016-08-18 | F. Hoffmann-La Roche Ag | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
WO2016133838A1 (en) | 2015-02-20 | 2016-08-25 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
WO2017135462A1 (ja) * | 2016-02-05 | 2017-08-10 | Eaファーマ株式会社 | 複素環スルホンアミド誘導体及びそれを含有する医薬 |
WO2017157885A1 (de) | 2016-03-16 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel |
WO2018015411A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
WO2018015410A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic proline compounds |
WO2018029288A1 (en) * | 2016-08-12 | 2018-02-15 | F. Hoffmann-La Roche Ag | Sulfonyl pyridyl trp inhibitors |
WO2018222795A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
EP3317258A4 (en) * | 2015-07-01 | 2019-06-26 | Pharmakea, Inc. | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF |
WO2019164778A1 (en) * | 2018-02-20 | 2019-08-29 | Genentech, Inc. | Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof |
WO2022058946A1 (fr) | 2020-09-18 | 2022-03-24 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d'alzheimer |
IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019124A (ja) * | 2017-07-19 | 2019-02-07 | 日本化薬株式会社 | ピラジン化合物 |
KR102006157B1 (ko) | 2018-03-22 | 2019-08-01 | (주)에스더블유엠 | 자율주행 차량의 주행 유도선 제공 방법 및 장치 |
KR102006158B1 (ko) | 2018-03-27 | 2019-08-01 | (주)에스더블유엠 | 차량 주행유도 장치 및 방법 |
KR102068473B1 (ko) | 2018-03-30 | 2020-02-11 | (주)에스더블유엠 | 차량 시뮬레이션 방법 및 장치 |
CN117468520A (zh) | 2019-03-28 | 2024-01-30 | 住友建机株式会社 | 挖土机及施工系统 |
CN111116456B (zh) * | 2019-12-26 | 2022-01-28 | 南通华祥医药科技有限公司 | 一种4,4-二氟哌啶盐酸盐的制备方法 |
CN112624966B (zh) * | 2020-12-25 | 2022-12-23 | 杭州澳赛诺生物科技有限公司 | 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0102324A2 (de) | 1982-07-29 | 1984-03-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US20020025313A1 (en) | 1992-07-27 | 2002-02-28 | Micklus Michael J. | Targeting of liposomes to the blood-brain barrier |
US20020038086A1 (en) | 2000-07-27 | 2002-03-28 | Hynynen Kullervo H. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US20030073713A1 (en) | 2000-10-30 | 2003-04-17 | Schoenhard Grant L. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030129186A1 (en) | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US20040131692A1 (en) | 2001-05-05 | 2004-07-08 | Joerg Kreuter | Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
US20040204354A1 (en) | 2002-12-03 | 2004-10-14 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
WO2012152983A1 (en) * | 2011-05-06 | 2012-11-15 | Orion Corporation | Phenyl- sulfonyl derivatives as mediators of trpa1 receptor activity for the treatment of pain |
WO2013108857A1 (ja) * | 2012-01-17 | 2013-07-25 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
JP2009096764A (ja) * | 2007-10-17 | 2009-05-07 | Japan Tobacco Inc | ピペリジン化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
JP2013028537A (ja) * | 2009-11-11 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | N−ベンジルアミド誘導体およびそれを含有する医薬組成物 |
RU2603770C2 (ru) * | 2014-11-28 | 2016-11-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Замещенные пиразинопиримидиноны как блокаторы trpa1 каналов, фармацевтическая композиция, способы их получения и применения |
-
2014
- 2014-10-09 BR BR112016002012A patent/BR112016002012A2/pt not_active Application Discontinuation
- 2014-10-09 RU RU2016115868A patent/RU2675792C2/ru not_active IP Right Cessation
- 2014-10-09 WO PCT/EP2014/071593 patent/WO2015052264A1/en active Application Filing
- 2014-10-09 MX MX2016002368A patent/MX363457B/es unknown
- 2014-10-09 JP JP2016522013A patent/JP2016532673A/ja active Pending
- 2014-10-09 PL PL14789194T patent/PL3055302T3/pl unknown
- 2014-10-09 HU HUE14789194A patent/HUE041652T2/hu unknown
- 2014-10-09 LT LTEP14789194.9T patent/LT3055302T/lt unknown
- 2014-10-09 CA CA2917193A patent/CA2917193A1/en not_active Abandoned
- 2014-10-09 EP EP14789194.9A patent/EP3055302B1/en active Active
- 2014-10-09 RS RS20190254A patent/RS58376B1/sr unknown
- 2014-10-09 SI SI201431098T patent/SI3055302T1/sl unknown
- 2014-10-09 TW TW103135249A patent/TWI657076B/zh not_active IP Right Cessation
- 2014-10-09 PT PT14789194T patent/PT3055302T/pt unknown
- 2014-10-09 DK DK14789194.9T patent/DK3055302T3/en active
- 2014-10-09 CN CN201480053713.2A patent/CN105612153B/zh active Active
- 2014-10-09 SG SG11201609411SA patent/SG11201609411SA/en unknown
- 2014-10-09 ES ES14789194T patent/ES2713323T3/es active Active
- 2014-10-09 KR KR1020167012211A patent/KR20160064230A/ko not_active Application Discontinuation
- 2014-10-09 TR TR2019/02249T patent/TR201902249T4/tr unknown
-
2016
- 2016-04-11 US US15/095,467 patent/US20160221945A1/en not_active Abandoned
- 2016-06-27 HK HK16107470.6A patent/HK1219478A1/zh unknown
-
2017
- 2017-12-21 US US15/851,322 patent/US20180118680A1/en not_active Abandoned
-
2018
- 2018-06-06 US US16/001,770 patent/US20180282272A1/en not_active Abandoned
- 2018-12-11 JP JP2018231696A patent/JP6735330B2/ja active Active
-
2019
- 2019-02-19 HR HRP20190329TT patent/HRP20190329T1/hr unknown
- 2019-10-18 US US16/657,102 patent/US11236046B2/en active Active
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A2 (de) | 1982-07-29 | 1984-03-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5506206A (en) | 1990-04-23 | 1996-04-09 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5686416A (en) | 1991-04-23 | 1997-11-11 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US20020025313A1 (en) | 1992-07-27 | 2002-02-28 | Micklus Michael J. | Targeting of liposomes to the blood-brain barrier |
US20020038086A1 (en) | 2000-07-27 | 2002-03-28 | Hynynen Kullervo H. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US20030073713A1 (en) | 2000-10-30 | 2003-04-17 | Schoenhard Grant L. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20040131692A1 (en) | 2001-05-05 | 2004-07-08 | Joerg Kreuter | Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
US20030129186A1 (en) | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US20050124533A1 (en) | 2002-02-27 | 2005-06-09 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability stan-261con |
US20040204354A1 (en) | 2002-12-03 | 2004-10-14 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
WO2012152983A1 (en) * | 2011-05-06 | 2012-11-15 | Orion Corporation | Phenyl- sulfonyl derivatives as mediators of trpa1 receptor activity for the treatment of pain |
WO2013108857A1 (ja) * | 2012-01-17 | 2013-07-25 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
Non-Patent Citations (48)
Title |
---|
"Fieser and Fieser's Reagents for Organic Synthesis", vol. 1-15, 1991, WILEY & SONS |
"Organic Reactions", vol. 1-40, 1991, WILEY & SONS |
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, 21ST ED. |
"Rodd's Chemistry of Carbon Compounds", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS |
AGOPYAN, N. ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOD., vol. 286, 2004, pages L563 - 72 |
AGOPYAN, N. ET AL., TOXICOL. APPL. PHARMACAL., vol. 192, 2003, pages 21 - 35 |
ANSEL, HOWARD C. ET AL.: "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, LIPPINCOTT, WILLIAMS & WILKINS |
ASAI, H. ET AL., PAIN, vol. 117, 2005, pages 19 - 29 |
BARTON ET AL., EXP. MOL. PATHOL., vol. 81, no. 2, 2006, pages 166 - 170 |
BOBO ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 91, 1994, pages 2076 - 2080 |
BOLCSKEI ET AL., PAIN, vol. 117, no. 3, 2005, pages 368 - 376 |
CHAN ET AL., LANCET, vol. 361, 2003, pages 385 |
DINIS, P. ET AL., J NEUROSCI., vol. 24, 2004, pages 11253 - 11263 |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3688 |
FLEISHER, D. ET AL.: "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", ADVANCED DRUG DELIVERY REVIEWS, vol. 19, 1996, pages 115 |
GENNARO, ALFONSO R. ET AL.: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS |
GEPPETTI, P. ET AL., BR. J. PHARMACAL., vol. 141, 2004, pages 1313 - 20 |
GHILARDI, J.R. ET AL., J. NEUROSCI., vol. 25, 2005, pages 3126 - 31 |
GILL ET AL., NATURE MED., vol. 9, 2003, pages 589 - 595 |
GOADSBY, CURR. PAIN HEADACHE REPORTS, vol. 8, 2004, pages 393 |
H. BUNDGAARD ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285 |
H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 1 - 38 |
H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER |
HONORE, P. ET AL., J PHARMACAL EXP THER., vol. 314, 2005, pages 410 - 21 |
HWANG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4030 |
J. MED. CHEM., vol. 39, 1996, pages 10 |
K. WIDDER, ET AL.: "Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 396 |
KIMBALL, E.S. ET AL., NEUROGASTROENTEROL. MOTIF., vol. 16, 2004, pages 811 |
KOSUGI ET AL., J.NEUROSCI, vol. 27, 2007, pages 4443 - 4451 |
KREMAYER ET AL., NEURON, vol. 66, 2010, pages 671 - 680 |
KROGSGAARD-LARSEN AND H. BUNDGAARD: "A Textbook of Drug Design and Development", 1991, article "Design and Application of Prodrugs (chapter 5)", pages: 113 - 191 |
LALLOO, U.G. ET AL., J. APPL. PHYSIOL., vol. 79, no. 4, 1995, pages 1082 - 7 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 |
MENENDEZ, L. ET AL., NEUROSCI. LETT., vol. 393, no. 1, 2005, pages 70 - 73 |
N. KAKEYA ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692 |
NEUWELT, E. A.: "Implication of the Blood-Brain Barrier and its Manipulation", vol. 1, 2, 1989, PLENUM PRESS |
PAPANASTASSIOU ET AL., GENE THERAPY, vol. 9, 2002, pages 398 - 406 |
POMONIS, J.D. ET AL., PHARMACAL. EXP. THER., vol. 306, 2003, pages 387 |
ROWE; RAYMOND C: "Handbook of Pharmaceutical Excipients", 2005, PHARMACEUTICAL PRESS |
SANCHEZ, M. ET AL., EUR J PHARMACAL., vol. 515, 2005, pages 20 - 27 |
SCULPTOREANU, A. ET AL., NEUROSCI LETT., vol. 381, 2005, pages 42 - 46 |
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 |
SZABO, A. ET AL., J. PHARMACAD. EXP. THER., vol. 314, 2005, pages 111 - 119 |
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis, 3rd ed.", 1999, JOHN WILEY AND SONS |
WALKER, K.M. ET AL., PHARMACAL. EXP. THER., vol. 304, no. 1, 2003, pages 56 - 62 |
WEI ET AL., NEUROSCI LETT, vol. 479, 2010, pages 253 - 256 |
WEI ET AL., PAIN, vol. 152, 2011, pages 582 - 591 |
YIANGOU, Y. ET AL., LANCET, vol. 357, 2001, pages 1338 - 39 |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018513107A (ja) * | 2015-02-15 | 2018-05-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 1−(het)アリールスルホニル−(ピロリジン又はピペリジン)−2−カルボキサミド誘導体、及びtrpa1拮抗薬としてのそれらの使用 |
WO2016128529A1 (en) * | 2015-02-15 | 2016-08-18 | F. Hoffmann-La Roche Ag | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
CN107922392B (zh) * | 2015-02-15 | 2020-07-21 | 豪夫迈·罗氏有限公司 | 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途 |
EA033497B1 (ru) * | 2015-02-15 | 2019-10-31 | Hoffmann La Roche | 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1 |
US10179782B2 (en) | 2015-02-15 | 2019-01-15 | Genentech, Inc. | Substituted sulfonamide compounds |
CN107922392A (zh) * | 2015-02-15 | 2018-04-17 | 豪夫迈·罗氏有限公司 | 1‑(杂)芳基磺酰基‑(吡咯烷或哌啶)‑2‑甲酰胺衍生物及其作为trpa1拮抗剂的用途 |
WO2016133838A1 (en) | 2015-02-20 | 2016-08-25 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
EP3317258A4 (en) * | 2015-07-01 | 2019-06-26 | Pharmakea, Inc. | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF |
AU2017213993B2 (en) * | 2016-02-05 | 2021-03-25 | Ea Pharma Co., Ltd. | Heterocyclic sulfonamide derivative and medicine containing same |
WO2017135462A1 (ja) * | 2016-02-05 | 2017-08-10 | Eaファーマ株式会社 | 複素環スルホンアミド誘導体及びそれを含有する医薬 |
CN108602807B (zh) * | 2016-02-05 | 2022-05-13 | Ea制药株式会社 | 杂环磺酰胺衍生物及含有其的药物 |
JPWO2017135462A1 (ja) * | 2016-02-05 | 2018-12-13 | Eaファーマ株式会社 | 複素環スルホンアミド誘導体及びそれを含有する医薬 |
CN108602807A (zh) * | 2016-02-05 | 2018-09-28 | Ea制药株式会社 | 杂环磺酰胺衍生物及含有其的药物 |
EA037264B1 (ru) * | 2016-02-05 | 2021-03-01 | Эа Фарма Ко., Лтд. | Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство |
US10584116B2 (en) | 2016-02-05 | 2020-03-10 | Ea Pharma Co., Ltd. | Heterocyclic sulfonamide derivative and medicine containing same |
WO2017157885A1 (de) | 2016-03-16 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel |
US10766878B2 (en) | 2016-07-20 | 2020-09-08 | Genentech, Inc. | Sulfonylcycloalkyl carboxamide compounds |
JP7043483B2 (ja) | 2016-07-20 | 2022-03-29 | エフ.ホフマン-ラ ロシュ アーゲー | 二環式プロリン化合物 |
JP2019521163A (ja) * | 2016-07-20 | 2019-07-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二環式プロリン化合物 |
JP2019525921A (ja) * | 2016-07-20 | 2019-09-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Trpa1モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物 |
WO2018015411A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
US20190144428A1 (en) * | 2016-07-20 | 2019-05-16 | Genentech, Inc. | Bicyclic proline compounds |
US10597383B2 (en) * | 2016-07-20 | 2020-03-24 | Genentech, Inc. | Bicyclic proline compounds |
CN109476640A (zh) * | 2016-07-20 | 2019-03-15 | 豪夫迈·罗氏有限公司 | 双环脯氨酸化合物 |
WO2018015410A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic proline compounds |
JP7071959B2 (ja) | 2016-08-12 | 2022-05-19 | エフ.ホフマン-ラ ロシュ アーゲー | スルホニルピリジルtrp阻害剤 |
US10695348B2 (en) | 2016-08-12 | 2020-06-30 | Genentech, Inc. | Sulfonyl pyridyl TRP inhibitors |
WO2018029288A1 (en) * | 2016-08-12 | 2018-02-15 | F. Hoffmann-La Roche Ag | Sulfonyl pyridyl trp inhibitors |
JP2019524818A (ja) * | 2016-08-12 | 2019-09-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | スルホニルピリジルtrp阻害剤 |
EP3929194A1 (en) | 2017-06-01 | 2021-12-29 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
WO2018222795A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
USRE49700E1 (en) | 2017-06-01 | 2023-10-17 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
WO2019164778A1 (en) * | 2018-02-20 | 2019-08-29 | Genentech, Inc. | Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof |
WO2022058946A1 (fr) | 2020-09-18 | 2022-03-24 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d'alzheimer |
FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11236046B2 (en) | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | |
US10179782B2 (en) | Substituted sulfonamide compounds | |
JP5703212B2 (ja) | キナーゼ阻害剤としてのピロロピリジン | |
AU2016366546B2 (en) | Inhibitors of Bruton's tyrosine kinase and methods of their use | |
EP2603500A1 (en) | Inhibitors of bruton's tyrosine kinase | |
TW201329067A (zh) | 作為gka活化劑之脲化合物 | |
WO2014121055A2 (en) | Flap modulators | |
EP3487853B1 (en) | Bicyclic proline compounds | |
WO2022165530A1 (en) | Small molecule inhibitors of salt inducible kinases | |
KR20230123471A (ko) | 화합물, 조성물 및 방법 | |
WO2023139085A1 (en) | New benzimidazole pyridine derivatives | |
WO2022073904A1 (en) | Mrgx2 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14789194 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2917193 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016002012 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/002368 Country of ref document: MX |
|
REEP | Request for entry into the european phase |
Ref document number: 2014789194 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014789194 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016522013 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20167012211 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016115868 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017140 Country of ref document: CR Ref document number: CR2017-000140 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 112016002012 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160128 |